Conference Coverage EHA 2022 – Focus on Multiple Myeloma

The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?

June 13, 2022

Faculty Chair

Rafael Fonseca, MD

Mayo Clinic, Phoenix, AZ, USA

Faculty Members

Suzanne Lentzsch, MD, PhD
Columbia University, New York, NY, USA

Irene Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, USA

María-Victoria Mateos, MD, PhD
University of Salamanca, Spain

Hermann Einsele, MD, FRCP
University Hospital Würzburg, Germany

Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University, Paris, France

Xavier Leleu, MD, PhD
Poitiers University Hospital, Poitiers, France

Sample Report

Start discovering the insights

View Report


  • First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma
  • First Line (2): Induction in Transplant-Eligible Multiple Myeloma
  • First Line (3): Maintenance and MRD
  • Relapsed/Refractory Multiple Myeloma: First and Second Relapse
  • Relapsed/Refractory Multiple Myeloma: Novel Agents
  • Relapsed/Refractory Multiple Myeloma: Antibodies and Bispecifics
  • Relapsed/Refractory Multiple Myeloma: CAR Ts

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.